The British maker of Theraflu and Flonase cold medicines and Sensodyne toothpaste reported first-half organic ​revenue growth of 2.6%, in line with forecasts, but meaning a stronger second half is needed to hit its medium-term target of 4% to 6% growth. Amid cautious consumer spending, Haleon has been expanding distribution and improving shelf positioning in the United States, its largest ‌market. STRONGER SECOND HALF"We're going to have a stronger second half than ​first ​half, and we're confident in that," CEO Brian ​McNamara told analysts, adding that growth ‌would be driven by some emerging markets and a recovery in demand for cough-and-cold products. Haleon's first-half adjusted operating profit of £1.36 billion ($1.81 billion) topped expectations of £1.32 billion in a company-compiled poll. Still, Jefferies analysts said: "This is not quite good enough, we think," arguing ‌that stronger underlying sales growth was needed.